메뉴 건너뛰기




Volumn 68, Issue 5, 2012, Pages 505-512

Off-label use of anti-cancer drugs between clinical practice and research: The Italian experience

Author keywords

Anti cancer drugs; Off label; Regulatory agencies

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DUTASTERIDE; EPIRUBICIN; FLUDARABINE; FLUOROURACIL; NAVELBINE; OXALIPLATIN; PACLITAXEL; RITUXIMAB; STEROID 5ALPHA REDUCTASE INHIBITOR; THALIDOMIDE; TRASTUZUMAB;

EID: 84864283129     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1173-6     Document Type: Review
Times cited : (29)

References (35)
  • 1
    • 41649086195 scopus 로고    scopus 로고
    • Regulating off-label drug use-rethinking the role of the FDA
    • Randall S, Stafford MD (2008) Regulating off-label drug use-rethinking the role of the FDA. N Engl J Med 358:1427-1429
    • (2008) N Engl J Med , vol.358 , pp. 1427-1429
    • Randall, S.1    Stafford, M.D.2
  • 2
    • 79959947866 scopus 로고    scopus 로고
    • Off-label drug utilization in oncology
    • De Souza JA (2011) Off-label drug utilization in oncology. Clin Adv Hematol Oncol 9:473-475
    • (2011) Clin Adv Hematol Oncol , vol.9 , pp. 473-475
    • De Souza, J.A.1
  • 3
    • 0037249993 scopus 로고    scopus 로고
    • Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children
    • DOI 10.1093/annonc/mdg031
    • Conroy S, Newman C, Gudka S (2003) Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann Oncol 14:42-47 (Pubitemid 36150257)
    • (2003) Annals of Oncology , vol.14 , Issue.1 , pp. 42-47
    • Conroy, S.1    Newman, C.2    Gudka, S.3
  • 5
    • 0036185967 scopus 로고    scopus 로고
    • Unlicensed and off-label drug use in children: Implications for safety
    • Choonara I, Conroy S (2002) Unlicensed and off-label drug use in children: implications for safety. Drug Saf 25:1-5 (Pubitemid 34208327)
    • (2002) Drug Safety , vol.25 , Issue.1 , pp. 1-5
    • Choonara, I.1    Conroy, S.2
  • 6
    • 0028950541 scopus 로고
    • Off-label drug prescribing on a state university obstetric service
    • Rayburn WF, Turnbull GL (1995) Off-label drug prescribing on a state university obstetric service. J Reprod Med 40:186-188
    • (1995) J Reprod Med , vol.40 , pp. 186-188
    • Rayburn, W.F.1    Turnbull, G.L.2
  • 8
    • 0026006906 scopus 로고
    • The off-label debate: A threat to the future of cancer care
    • Mortenson LE (1991) The off-label debate: a threat to the future of cancer care. Cancer Investig 9:597-599
    • (1991) Cancer Investig , vol.9 , pp. 597-599
    • Mortenson, L.E.1
  • 9
    • 33947313964 scopus 로고    scopus 로고
    • (Last Medical Review: March 14, 2011)
    • The American Cancer Society: Off-label drug use. Available at: http://www.cancer.org/Treatment/TreatmentsandSideEffects/TreatmentTypes/ Chemotherapy/off-label-drug-use. (Last Medical Review: March 14, 2011)
    • The American Cancer Society: Off-label Drug Use
  • 10
    • 20344384566 scopus 로고    scopus 로고
    • Évaluation des indications hors AMM chez des patients adultes traités par chimiothérapie anticancéreuse
    • Levêque D, Michallat AC, Schaller C, Ranc M (2005) Off label drug use in adult patients treated by anticancer chemotherapy. Bull Cancer 92:498-500 (Pubitemid 40852766)
    • (2005) Bulletin du Cancer , vol.92 , Issue.5 , pp. 498-500
    • Leveque, D.1    Michallat, A.C.2    Schaller, C.3    Ranc, M.4
  • 11
    • 2442511933 scopus 로고    scopus 로고
    • Off-label prescribing in oncology
    • DOI 10.1007/s00520-004-0593-6
    • Poole SG, Dooley MJ (2004) Off-label prescribing in oncology. Support Care Cancer 12:302-305 (Pubitemid 38647853)
    • (2004) Supportive Care in Cancer , vol.12 , Issue.5 , pp. 302-305
    • Poole, S.G.1    Dooley, M.J.2
  • 12
    • 84855166849 scopus 로고    scopus 로고
    • Off-label drug use in women with breast cancer
    • abstract 1016
    • Dean-Colombo W, Fang S, Smith W et al (2009) Off-label drug use in women with breast cancer. J Clin Oncol 27[15 suppl]:abstract 1016
    • (2009) J Clin Oncol , vol.27 , Issue.15 SUPPL.
    • Dean-Colombo, W.1    Fang, S.2    Smith, W.3
  • 13
    • 0038182599 scopus 로고    scopus 로고
    • Effect of off-label use of oncology drugs on pharmaceutical costs: The rituximab experience
    • Kocs D, Fendrick AM (2003) Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care 9:393-400 (Pubitemid 36617254)
    • (2003) American Journal of Managed Care , vol.9 , Issue.5 , pp. 393-400
    • Kocs, D.1    Fendrick, A.M.2
  • 14
    • 76349124677 scopus 로고    scopus 로고
    • Off-label prescription of antineoplastic drugs: An Italian prospective, observational, multi center survey
    • Roila F, Ballatori E, Labianca R et al (2009) Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multi center survey. Tumori 95:647-651
    • (2009) Tumori , vol.95 , pp. 647-651
    • Roila, F.1    Ballatori, E.2    Labianca, R.3
  • 15
  • 16
    • 79957965504 scopus 로고    scopus 로고
    • Evaluation of oncology drugs at the European medicines agengy and US food and drug administration: When differences have an impact on clinical practice
    • Trotta F, Leufkens HGM, Schellens JHM et al (2011) Evaluation of oncology drugs at the European medicines agengy and US food and drug administration: when differences have an impact on clinical practice. J Clin Oncol 29:2266-2272
    • (2011) J Clin Oncol , vol.29 , pp. 2266-2272
    • Trotta, F.1    Leufkens, H.G.M.2    Schellens, J.H.M.3
  • 17
    • 59049104106 scopus 로고    scopus 로고
    • Rationing new medicines in the UK
    • Drummond M, Mason A (2009) Rationing new medicines in the UK. Br Med J 338:a3182
    • (2009) Br Med J , vol.338
    • Drummond, M.1    Mason, A.2
  • 18
    • 77954707651 scopus 로고    scopus 로고
    • Comparison of anticancer drug coverage decisions in the United States and United Kingdom: Does the evidence support the rhetoric?
    • Mason A, Drummond M, Ramsey S et al (2010) Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol 28:3234-3238
    • (2010) J Clin Oncol , vol.28 , pp. 3234-3238
    • Mason, A.1    Drummond, M.2    Ramsey, S.3
  • 19
    • 64049108287 scopus 로고    scopus 로고
    • Public funding of new cancer drugs: Is NICE getting nastier?
    • Mason AR, Drummond MF (2009) Public funding of new cancer drugs: is NICE getting nastier? Eur J Cancer 45:1188-1192
    • (2009) Eur J Cancer , vol.45 , pp. 1188-1192
    • Mason, A.R.1    Drummond, M.F.2
  • 20
    • 83255187283 scopus 로고    scopus 로고
    • A role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use, reply to letter
    • [Epub ahead of print]
    • Duran-Garcia E, Santos-Ramos B, Puigventos-Latorre F, Ortega (2011) A role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use, reply to letter. Int J Clin Pharm [Epub ahead of print]
    • (2011) Int J Clin Pharm
    • Duran-Garcia, E.1    Santos-Ramos, B.2    Puigventos-Latorre, F.3    Ortega4
  • 21
    • 84864284204 scopus 로고    scopus 로고
    • Assises de médicament Groupe 3 "Encadrer les prescriptions hors AMM" Accessed 15 Sept 2011
    • Assises de médicament Groupe 3 "Encadrer les prescriptions hors AMM" (2011). Dispositifs dérogatoires de prescription "hors AMM". Available at: http://www.sante.gouv.fr/IMG/pdf/ Dispositifs-derogatoires-de-prescription-hors-AMM-.pdf Accessed 15 Sept 2011
    • (2011) Dispositifs Dérogatoires de Prescription "hors AMM"
  • 22
    • 85052777310 scopus 로고    scopus 로고
    • Agenzia Italiana del Farmaco Accessed 15 Sept 2011
    • Agenzia Italiana del Farmaco (2007) Registro Farmaci Oncologici sottoposti a monitoraggio, Rapporto 2007. Available at http://antineoplastici. agenziafarmaco.it/Registro-farmaci.pdf Accessed 15 Sept 2011
    • (2007) Registro Farmaci Oncologici Sottoposti a Monitoraggio, Rapporto 2007
  • 23
    • 34247362067 scopus 로고    scopus 로고
    • Reimbursement for cancer treatment: Coverage of off-label drug indications
    • American Society of Clinical Oncology
    • American Society of Clinical Oncology (2006) Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol 24:3206-3208
    • (2006) J Clin Oncol , vol.24 , pp. 3206-3208
  • 24
    • 54349129587 scopus 로고    scopus 로고
    • Off-label use of anticancer drugs
    • Levêque D (2008) Off-label use of anticancer drugs. Lancet Oncol 9:1102-1107
    • (2008) Lancet Oncol , vol.9 , pp. 1102-1107
    • Levêque, D.1
  • 25
    • 59749092456 scopus 로고    scopus 로고
    • Limits on Medicare's ability to control rising spending on cancer drugs
    • Bach PB (2009) Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633
    • (2009) N Engl J Med , vol.360 , pp. 626-633
    • Bach, P.B.1
  • 26
    • 77954651388 scopus 로고    scopus 로고
    • Uncertainty in assessing value of oncology treatments
    • Mullins CD, Montgomery R, Tunis R (2010) Uncertainty in assessing value of oncology treatments. Oncologist 15:58-64
    • (2010) Oncologist , vol.15 , pp. 58-64
    • Mullins, C.D.1    Montgomery, R.2    Tunis, R.3
  • 27
    • 33845429035 scopus 로고    scopus 로고
    • Off-label-use in der onkologie: Ein thema ohne ende?
    • DOI 10.1007/s00120-006-1223-3
    • Weißbach L, Riese J (2006) Off-label use in oncology: an inexhaustible topic? Urologe A 45(11):1410-1414 (Pubitemid 44900216)
    • (2006) Urologe - Ausgabe A , vol.45 , Issue.11 , pp. 1410-1414
    • Weissbach, L.1    Riese, J.2
  • 28
    • 0037146340 scopus 로고    scopus 로고
    • Demand grows for early access to promising cancer drugs
    • Baldwin J (2002) Demand grows for early access to promising cancer drugs. J Natl Cancer Inst 94:1668-1670
    • (2002) J Natl Cancer Inst , vol.94 , pp. 1668-1670
    • Baldwin, J.1
  • 31
    • 37549040613 scopus 로고    scopus 로고
    • Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    • Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
    • (2007) N Engl J Med , vol.357 , pp. 2666-2676
    • Miller, K.1    Wang, M.2    Gralow, J.3
  • 32
    • 63049099067 scopus 로고    scopus 로고
    • Use of 5-α-Reductase inhibitors for prostate cancer chemoprevention: American Society of clinical Oncology/American Urological association 2008 clinical practice guideline
    • Kramer BS, Hagerty KL, Justman S et al (2009) Use of 5-α-Reductase inhibitors for prostate cancer chemoprevention: American Society of clinical Oncology/American Urological association 2008 clinical practice guideline. J Clin Oncol 27:1502-1516
    • (2009) J Clin Oncol , vol.27 , pp. 1502-1516
    • Kramer, B.S.1    Hagerty, K.L.2    Justman, S.3
  • 33
    • 77950498003 scopus 로고    scopus 로고
    • Effect of dutasteride on the risk of prostate cancer
    • Andriole GL, Bostwick D, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192-1202
    • (2010) N Engl J Med , vol.362 , pp. 1192-1202
    • Andriole, G.L.1    Bostwick, D.2    Brawley, O.W.3
  • 34
    • 37349006685 scopus 로고    scopus 로고
    • The off-label use of drugs in oncology: A position paper by the European Society for Medical Oncology (ESMO)
    • DOI 10.1093/annonc/mdm517
    • Casali PG (2007) The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 18:1923-1925 (Pubitemid 350286226)
    • (2007) Annals of Oncology , vol.18 , Issue.12 , pp. 1923-1925
    • Casali, P.G.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.